In today’s briefing:
- CleanSpace Holdings RaaS Interview Transcript
- Cleanspace Holdings Ltd – Spotless numbers
- Olympus Corp (7733 JP): Concerns Remain; Green Shoots Appear; Better To Wait and Watch
- Shanghai Fosun Pharmaceutical (2196.HK/600196.CH) 25H1 – The Performance Has Not Truly Improved
- Sino Biopharmaceutical (1177 HK): Innovative Drugs Drive 1H Performance; Pipeline Lends Visibility
CleanSpace Holdings RaaS Interview Transcript
- Finola Burke from RaaS Research Group interviews CleanSpace Holdings’ CEO Gabrielle O’Carroll and CFO Bree Greeff.
Cleanspace Holdings Ltd – Spotless numbers
- CleanSpace Holdings Ltd (ASX:CSX) is a designer and manufacturer of respiratory protection equipment and consumables for powered air purifying respirators (PAPRs).
- CSX has released its FY25 results delivering an impressive set of numbers including revenue growth of 26%, a 250bps increase in gross margin to 74.8%, flat costs on the pcp despite some one-offs, a H2 FY25 EBITDA profit and positive operating cash flow.
- Inventories relative to sales declined 700bps to 11%, helping to boost cash reserves to $10.5m.
Olympus Corp (7733 JP): Concerns Remain; Green Shoots Appear; Better To Wait and Watch
- Olympus Corp (7733 JP) witnessed revenue decline of 12% YoY to ¥206.5B (down 7% on Fx neutral) in Q1FY26 due to a high base effect coupled with delayed purchase decisions.
- The company revised full-year forecasts mainly due to the impact of the U.S. tariffs and FDA import alerts.
- Olympus entered into an agreement with Revival Healthcare Capital forming a joint venture company named Swan EndoSurgical, dedicated to developing an innovative endoluminal robotic system for less invasive therapeutic treatments.
Shanghai Fosun Pharmaceutical (2196.HK/600196.CH) 25H1 – The Performance Has Not Truly Improved
- After excluding gains on the disposal of United Family Healthcare, profitability of main business was disappointing.The revenue decline confirms that Fosun Pharma is facing pressure. Short-term performance hasn’t truly improved.
- Fosun Pharma will continue to sell unprofitable assets to alleviate debt pressure and optimize business structure, which will be the short-term main theme. Fosun Pharma is still in adjustment period
- Whether high profit growth can be sustainable in long term is uncertain, which depends on if Henlius is able to achieve high growth to offset the negative impact of VBP.
Sino Biopharmaceutical (1177 HK): Innovative Drugs Drive 1H Performance; Pipeline Lends Visibility
- Sino Biopharmaceutical (1177 HK) announced 11% YoY revenue growth in 1H25, driven by 27% YoY growth in innovative products. Contribution of innovative drugs to total revenue increased to 44.4%.
- With the increasing contribution of innovative drugs to total revenue, gross profit margin expanded 40bps to 82.5%. With expanding margin and cost efficiency, net profit has more than doubled.
- The company expects to have more than 35 marketed innovative products by 2027, with revenue from innovative products accounting for over 60% of total revenue.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
